title: Twist form of teleocidin derivatives is active in in vivo tumor promotion by (-)-benzolactam-V8-310.
abstract: Teleocidin derivatives and the core structure, (-)-indolactam-V ((-)-IL-V), adopt two conformations in solution, the "twist" and the "sofa" forms. (-)-Benzolactam-V8-310 ((-)-BL-V8-310), which specifically adopts the twist form in solution, has been reported to have a significant effect on HL-60 cells and protein kinase C affinity. In this paper, we describe the biological activity with regard to tumor promotion on mouse skin and the wide variety of biological activity of (-)-BL-V8-310 and its derivatives. In both twist and sofa forms (-)-BL-V8-310 inhibited specific 3H-12-O-tetradecanoylphorbol-13-acetate (TPA) binding to a particulate fraction of mouse skin more strongly than (-)-IL-V. The doses for 50% inhibition (IC50) of (-)-IL-V, (-)-BL-V8-310, and teleocidin B-4 were 1000, 400 and 12 nM, respectively. As for the induction of tumor necrosis factor-alpha (TNF-alpha) release into the medium from HL-60 cells, the EC200 values, which are the concentrations of the compound required to achieve 200 pg/ml TNF-alpha in the medium, were 1700, 500 and 19 nM for (-)-IL-V, (-)-BL-V8-310 and teleocidin B-4, respectively. The same amounts (5.5 nmol per application) of (-)-BL-V8-310 and teleocidin B-4, induced tumors on mouse skin initiated with 7,12-dimethylbenz(a)anthracene (DMBA) in 13.3% and 86.7% of tumor-bearing mice, respectively, in week 20. These results confirmed that the twist form of teleocidin derivatives is the active form as far as the induction of biological activity is concerned. Also (-)-BL-V8-310 is a new synthetic tumor promoter designed from data obtained using the receptor cavity model of TPA-type tumor promoters.
authors.affiliation: Saitama Cancer Center Research Institute, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Okabe
authors.forename: N
authors.initials: N
authors.lastname: Sueoka
authors.forename: A
authors.initials: A
authors.lastname: Komori
authors.forename: M
authors.initials: M
authors.lastname: Suganuma
authors.forename: Y
authors.initials: Y
authors.lastname: Endo
authors.forename: K
authors.initials: K
authors.lastname: Shudo
authors.forename: H
authors.initials: H
authors.lastname: Fujiki
mesh_terms: D000818:Animals; D002273:Carcinogens / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D018922:HL-60 Cells; D006801:Humans; D007769:Lactams / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D008235:Lyngbya Toxins / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008968:Molecular Conformation; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D002273:Carcinogens; D007769:Lactams; D008235:Lyngbya Toxins; D014409:Tumor Necrosis Factor-alpha; C113786:benzolactam V8-310; C022176:teleocidins; D013755:Tetradecanoylphorbol Acetate